Tivic Health Systems, Inc. is changing its corporate name to Valion Bio, Inc. effective April 28, 2026. The company will trade under the new ticker symbol 'VBIO' on the Nasdaq Capital Market starting April 28, 2026. The rebrand marks the completion of a strategic shift from a consumer medical device business to a biopharmaceutical company focused on the drug candidate Entolimod. Entolimod is a TLR5 agonist for Acute Radiation Syndrome (ARS) with over $140 million in historical development investment. The company owns Velocity Bioworks, a CDMO subsidiary acquired for $16.3 million in December 2025, to provide internal manufacturing and third-party revenue.